ADMA ADMA Biologics Inc

4.51
-0.11  -2%
Previous Close 4.62
Open 4.57
Price To Book 10.49
Market Cap 209047701
Shares 46,353,068
Volume 271,589
Short Ratio
Av. Daily Volume 1,292,186

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

FDA Approval announced April 1, 2019.
RI-002
Primary Immune Deficiency Diseases
Response to Complete Response Letter submitted January 7, 2019.
BIVIGAM
Primary humoral immunodeficiency

Latest News

  1. ADMA Biologics Granted U.S. Patent for Treatment and Prevention of Pneumococcal Infections
  2. ADMA Biologics: Wall Street Projects Robust Revenue Growth
  3. Why ADMA Biologics Stock Soared Yesterday
  4. The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings
  5. ADMA Receives Department of Health and Human Services U.S. License
  6. ADMA Biologics Rips Higher On FDA Nod For Immunodeficiency Therapy
  7. ADMA Biologics' stock rockets on heavy volume after FDA approval of immunodeficiency treatment
  8. The Daily Biotech Pulse: FDA Nod For ADMA, Regulatory Setback For Apyx, Achieve Life Sciences Smoking Cessation Drug Trial
  9. FDA Approves ASCENIV™, a Novel Intravenous Immune Globulin
  10. Adma Biologics: 4Q Earnings Snapshot
  11. ADMA Biologics Reports Full Year 2018 Financial Results
  12. ADMA Biologics to Present at Upcoming Investor Conferences
  13. Watch These Tech Stocks Set The Pace On Tuesday 2/12/19
  14. ADMA Biologics Enters Into $72.5 Million Loan Facility with Perceptive Advisors
  15. ADMA Biologics Submits Response and Provides Supplemental Information to FDA for BIVIGAM® Complete Response Letter
  16. Have Insiders Been Buying ADMA Biologics, Inc. (NASDAQ:ADMA) Shares This Year?
  17. Here is What Hedge Funds Think About ADMA Biologics Inc (ADMA)
  18. Here's Why ADMA Biologics Is Getting Hammered Today
  19. ADMA to Host Conference Call to Discuss Recent Regulatory Update on BIVIGAM® PAS Submissions
  20. FDA declines to approve re-launch of ADMA Biologics' Bivigam